Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.

Clinical trial NCT07755436 · RECRUITING

Trial details

NCT number: NCT07755436
Sponsor: ArriVent BioPharma, Inc.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Ovarian Cancer Endometrial Cancer Platinum-resistant Ovarian Cancer (PROC)Metastatic Ovarian Cancer Metastatic Endometrial Cancer

Start date: 2026-07-23
Primary completion: 2027-08-01
Enrollment: 180

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.